<DOC>
	<DOCNO>NCT00625703</DOCNO>
	<brief_summary>To determine pharmacokinetic profile IV ( intravenous ) PO ( oral ) formulation linezolid among child cystic fibrosis establish dose regimen safe effective .</brief_summary>
	<brief_title>Pharmacokinetics Linezolid Children With Cystic Fibrosis</brief_title>
	<detailed_description>Patients cystic fibrosis pulmonary exacerbation associate isolation MRSA sputum identify primary physician laboratory record review . If meet inclusion criterion , invite participate study . The primary outcome variable include pharmacokinetic pharmacodynamic index . The study end point include completion sputum blood sample pharmacokinetic study intravenous oral formulation linezolid collection microbiologic specimen ( sputum anterior naris culture ) one month discharge . Additionally , pharmacokinetic data analyze effect age CFTR mutation clearance linezolid relationship level linezolid achieve sputum blood clinical outcome</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Subjects &lt; 18 year age inclusive , confirmed diagnosis cystic fibrosis admit hospital acute pulmonary exacerbation MRSA isolate sputum culture . Female subject childbearing potential must negative pregnancy test prior first dose study drug , sexually active agrees use acceptable method birth control per investigator judgment duration study . Subjects receive medication serotonergic ( certain type antidepressant ) adrenergic activity discontinue base clinical judgment primary physician may enrol . These subject monitor closely serotonin sympathomimeticassociated toxicity . Subject ( able ) subject 's parent /legal guardian agree comply study requirement . Subject sufficient venous access permit administration study medication , collection pharmacokinetic sample monitor safety variable . Duration linezolid therapy expect exceed 7 day . English Spanishspeaking subject . Subjects clinical laboratory evidence severe hepatic ( ChildPugh class C ) disease Subjects severe renal impairment ( estimate creatinine clearance &lt; 30 mL/min ) Subjects history allergy linezolid . Pregnant breastfeeding subject .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Pharmacokinetic</keyword>
</DOC>